Results 101 to 110 of about 1,050,726 (302)

Antimicrobial resistance and genetic characterization of Clostridium perfringens isolated from companion animals in South Korea, 2018–2024

One Health
Clostridium perfringens is an emerging pathogenic bacterium associated with various gastrointestinal diseases in humans and animals. We aimed to investigate the prevalence, antimicrobial resistance, and molecular characteristics of C.
Ji-Hyun Choi, Md. Sekendar Ali, Yeon-Hee Lee, Hee-Seung Kang, Seung-Chun Park, Bo-Youn Moon, Suk-Kyung Lim   +6 more
doaj   +1 more source

Invasive bacterial disease in young infants in rural Gambia: Population-based surveillance. [PDF]

J Glob Health, 2023
Olatunji YA, Banjo AA, Jarde A, Salaudeen R, Ndiaye M, Galega LB, Odutola A, Hossain IM, Osuorah C, Sahito MS, Muhammad BS, Ikumapayi NU, Drammeh MM, Manjang A, Adegbola RA, Greenwood BM, Hill PC, Grant MA.   +17 more
europepmc   +1 more source

Longitudinal Assessment of Biomarkers in ALS: Discriminative Biomarkers for Disease Progression and Survival

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To assess the association and discriminative performance of serum biomarkers with clinical disease progression and survival in patients with amyotrophic lateral sclerosis (ALS). Methods This retrospective study, conducted at Houston Methodist Hospital, Houston, TX, used longitudinal serum samples collected between January 2018 and ...
David R. Beers, Yueh‐Yun Lin, Jason R. Thonhoff, Aaron D. Thome, Alireza Faridar, Weihua Zhao, Shixiang Wen, Stanley H. Appel   +7 more
wiley   +1 more source

Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Haemophilus influenzae, 2020 [PDF]

Dataset version: Jul 2022; Final run: Sep 20, 2022Citation: Centers for Disease Control and Prevention. 2020. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Haemophilus influenzae, 2020.

core  

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network : Group B Streptococcus, 2019 [PDF]

Citation: Centers for Disease Control and Prevention. 2019. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2019.

core  

Editorial: Molecular mechanisms of bacterial disease in cultured fishes. [PDF]

Front Vet Sci, 2022
Najiah M, Huang L, Pang H, Ebani VV.
europepmc   +1 more source

CAR T‐Cell Therapy in Neurology: A Scoping Review of Neuro‐Oncology, Autoimmune Diseases & Neurotoxicity

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi, Mohammed Dibas, Patricia Tai, Ala Dibas, Osama Souied, Suhair Al‐Ghabeesh   +5 more
wiley   +1 more source

Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Group A Streptococcus, 2020 [PDF]

Dataset version: Jul 2022 Final run: Sep 20, 2022Citation: Centers for Disease Control and Prevention. 2020. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A Streptococcus, 2020.Publication date from document ...

core  

Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree, Beatrice Suero, Sarah Walsh, Romain Marignier, John W. Lindsey, Ho Jin Kim, Dewei She, Daniel Cimbora, Dustin Cavida, Friedemann Paul   +9 more
wiley   +1 more source